Summary We have previously developed a daunorubicin resistant subline of Ehrlich ascites carcinoma (EA/DR) for studies on the reversal of daunorubicin resistance. The mean survival of untreated BALB/c mice bearing drug sensitive parental tumour (EA/DS) is 18.4+0.6 days, mice bearing EA/DS treated with five daily doses of 0.3mgkg-' daunorubicin greater than 60 days, and mice bearing EA/DR treated with the same daunorubicin regimen, 21.1 + 1.4 days. We now report complete reversal of daunorubicin resistance in EA/DR by cyclosporin A (CsA). The in vitro daunorubicin IC50, defined as that concentration of daunorubicin required to inhibit 50% of DNA synthesis, in EA/DR was 6.7+1.15pgml-1 compared to 2.8+0.72 pgml-I in EA/DS. This value was reduced to 2.8+0.52 and 2.1 +0.opgml-Idaunorubicin by 3.3 and 13.2 pgml-1 CsA respectively, P<0.05. The MST of groups of host mice bearing EA/DR either untreated, treated with five daily doses of 0.3mgkg-' daunorubicin, treated with 80mgkg-' CsA in five divided daily doses or treated with combined daunorubicin-CsA were 19.0+1.0, 21.1+1.4, 24.0+2.6 and >60 days respectively. The mean survival of groups of host mice bearing EA/DR treated with 5mgkg-1 or 10mgkg-1 CsA simultaneously with daunorubicin for five days was also greater than 60 days. These differences are highly significant.
The development of resistance to chemotherapeutic drugs by neoplastic cells is a major obstacle to the cure of many malignancies. Recent reports indicate that it is possible to reverse resistance to vincristine and to daunorubicin in murine tumours in vivo by use of verapamil hydrochloride, the calcium channel blocking agent (Tsuruo et al., 1981; Slater et al., 1982; Xkovsgaard et al., 1984) . The use of verapamil in patients with malignancy has, however, been limited by high concentration requirements (Kessel & Wilberding, 1985a) . We now describe complete reversal of daunorubicin resistance in daunorubicin resistant Ehrlich ascites carcinoma by cyclosporin A used in doses previously employed in humans.
Materials and methods Tumour lines and treatment regimens Ehrlich ascites carcinoma (EA) was maintained as an ascitic tumour in BALB/c mice. A daunorubicinresistant subline was developed by sequential transfer of EA cells to subsequent generations of host mice with continuous daunorubicin treatment as previously described (Slater et al., 1982) . For current studies, the daunorubicin treatment regimen consists of 0.3mgkg-' daunorubicin i.p. daily for five doses, starting 24h after the inoculation of 0.2ml, i.p. of undiluted malignant ascites harvested from preterminal animals. CsA (Sandimmune I.V., Sandoz LTD) is given i.p. either alone or simultaneously with daunorubicin at the doses indicated.
Daunorubicin inhibition of [3H]-thymidine incorporation
Nucleotide incorporation studies were performed by the following method as previously described (Slater et al., 1982) . Cells were counted on a haemocytometer using dye exclusion, washed and resuspended in RPMI 1640 at a concentration of 2.5 x 106 ml-1. Cell aliquots of 1.6 ml were incubated with 0.2 ml daunorubicin HCI (final concentration 0-12pgml-1) and 0. (Slater et al., 1982) . In vivo, the addition of CsA to daunorubicin in the treatment of EA/DR bearing host mice also restores responses to daunorubicin. When CsA is added to the daunorubicin treatment of the resistant subline, the reduced survival of host mice bearing daunorubicin resistant EA treated with daunorubicin alone returns to the survival characteristic of host mice bearing daunorubicin sensitive EA.
Although the doses of CsA used in these in vivo murine studies are similar to those previously employed in humans (Biggs et al., 1983; Kennedy et al., 1985) the use of intraperitoneal CsA in the treatment of an ascitic tumour would favour high local drug concentrations. It is of interest, however, that tissue levels of CsA determined at postmortem examination in patients maintained on CsA for over one week until death range from several hundred to over 7000ngg-1 of tissue wet weight (Ried et al., 1983) . These values compare favourably to the 3300ngml-' CsA concentration demonstrated to reverse daunorubicin resistance in EA in vitro. Although the efficacy of CsA in reversing drug resistance of human tumours in vivo has not yet been demonstrated, we do note important in vitro activity of CsA in daunorubicin resistant human acute lymphatic leukaemia. CsA completely reverses 50-fold primary resistance to vincristine and 5-fold cross resistance to daunorubicin in a pleiotropic drug resistant subline of GM3639 human T cell acute lymphatic leukaemiaHuman Genetic Mutant Cell Repository, Camden, New Jersey (Slater et al., 1986) .
The mechanism by which CsA restores responses to daunorubicin and to vincristine is unclear, but may relate to its ability to inhibit calmodulin (Colombani et al., 1985) . Verapamil and calmodulin inhibitors have been shown to correct the enhanced active efflux of vinca alkaloids and anthracycline antibiotics characteristic of drug resistant tumour cells resulting in increased cellular drug retention (Tsuruo et al., 1981; . However, Kessel & Corbett (1985) were unable to demonstrate a correlation between adriamycin uptake and adriamycin resistance in murine solid tumours rendered resistant to adriamycin by in vivo drug exposure. We were similarly unable to detect significant differences in daunorubicin uptake between our daunorubicin-sensitive and daunorubicin-resistant Ehrlich ascites carcinoma subline and drug sensitive versus pleiotropic drug resistant human acute lymphatic leukaemia subline (Slater et al., 1986) , suggesting that the mechanism of CsA effect lies beyond the modification of drug transport. Since the acquisition of equimolar concentrations of anthracyclines by anthracycline resistant compared to anthracycline sensitive tumour cells fails to restore equivalent cytotoxic drug effect to these cells (Kessel & Wilberding, 1985b; Sikic et al., 1985) , the mechanism by which calcium channel blocking agents and calmodulin inhibitors restore drug sensitivity must extend beyond drug retention. It has been shown that adriamycin is cytotoxic when the drug is bound to polygluteraldehyde microspheres or to agarose, which prevents its entry into tumour cells and suggests that cytotoxicity occurs as a cell surface phenomenon (Tritton & Yee, 1982; Rogers et al., 1983) . The mechanism of anthracycline antibiotic resistance relates to the cell membrane as well, since recent reports show that pleiotropic drug resistant cells possess characteristic cell membrane glycoprotein alterations in addition to the enhanced active drug efflux described above (Kartner et al., 1983a,b) .
The studies of LeGrue et al. (1983) (Beck, 1983; Kessel & Wilberding, 1985b) .
